S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway

Brain

Volumn 135, Issue 11, 2012, Pages 3336-3347

  Sathe, Kinnari ^a   Maetzler, Walter ^b,c   Lang, Johannes D ^b,c   Mounsey, Ross B ^a   Fleckenstein, Corina ^d   Martin, Heather L ^a   Schulte, Claudia ^b,c   Mustafa, Sarah ^a   Synofzik, Matthis ^b,c   Vukovic, Zvonimir ^d   Itohara, Shigeyoshi ^e   Berg, Daniela ^b,c   Teismann, Peter ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d Diasorin SpA   (Italy)

^e RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

calcium binding protein; MPTP; Parkinson's disease; S100B

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; PROTEIN S100B; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; FEMALE; GLIOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANTIA NIGRA; UPREGULATION;

EID: 84870168829     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws250     Document Type: Article

References (49)

1. Adami C, Bianchi R, Pula G, Donato R. S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain. Biochim Biophys Acta 2004; 1742: 169-77.
2. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-Transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816-22.
3. Bianchi R, Adami C, Giambanco I, Donato R. S100B binding to RAGE in microglia stimulates COX-2 expression. J Leukoc Biol 2007; 81: 108-18.
4. Bianchi R, Kastrisianaki E, Giambanco I, Donato R. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem 2011; 286: 7214-26.
5. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-Associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-808.
6. Braak H, Sastre M, Del Tredici K. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol 2007; 114: 231-41.
7. Businaro R, Leone S, Fabrizi C, Sorci G, Donato R, Lauro GM, et al. S100B protects LAN-5 neuroblastoma cells against Abeta amyloid-induced neurotoxicity via RAGE engagement at low doses but increases Abeta amyloid neurotoxicity at high doses. J Neurosci Res 2006; 83: 897-906.
8. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta 1999; 1450: 191-231.
9. Halliday GM, Stevens CH. Glia: initiators and progressors of pathology in Parkinson's disease. Mov Disord 2011; 26: 6-17.
10. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
11. Hu J, Ferreira A, Van Eldik LJ. S100beta induces neuronal cell death through nitric oxide release from astrocytes. J Neurochem 1997; 69: 2294-301.
12. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem 2001; 81: 102-13.
13. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000; 275: 40096-105.
14. Iuvone T, Esposito G, De Filippis D, Bisogno T, Petrosino S, Scuderi C, et al. Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. J Mol Med 2007; 85: 1379-92.
15. Kerkhoff C, Klempt M, Sorg C. Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). Biochim Biophys Acta 1998; 1448: 200-11.
16. Kleindienst A, Meissner S, Eyupoglu IY, Parsch H, Schmidt C, Buchfelder M. Dynamics of S100B release into serum and cerebrospinal fluid following acute brain injury. Acta Neurochir Suppl 2010; 106: 247-50.
17. Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000; 16: 724-39.
18. Kogel D, Peters M, Konig HG, Hashemi SM, Bui NT, Arolt V, et al. S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: clinical implications for the role of S100B in excitotoxic brain injury. Neuroscience 2004; 127: 913-20.
19. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-Analog synthesis. Science 1983; 219: 979-80.
20. Langston JW, Irwin I. MPTP: current concepts and controversies. Clin Neuropharmacol 1986; 9: 485-507.
21. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2011; 285: 9262-72.
22. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-66.
23. Li Y, Barger SW, Liu L, Mrak RE, Griffin WS. S100beta induction of the proinflammatory cytokine interleukin-6 in neurons. J Neurochem 2000; 74: 143-50.
24. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999; 5: 1403-9.
25. Liu J, Shi Y, Tang J, Guo T, Li X, Yang Y, et al. SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem Biophys Res Commun 2005; 328: 335-41.
26. Maetzler W, Schmid SP, Wurster I, Liepelt I, Gaenslen A, Gasser T, et al. Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord 2011a; 26: 176-81.
27. Maetzler W, Stapf AK, Schulte C, Hauser AK, Lerche S, Wurster I, et al. Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-beta pathway. J Alzheimers Dis 2011b; 27: 119-26.
28. Mokuno K, Kato K, Kawai K, Matsuoka Y, Yanagi T, Sobue I. Neuronspecific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases. J Neurol Sci 1983; 60: 443-51.
29. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, et al. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005; 19: 164-70.
30. Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J Neuropathol Exp Neurol 1996; 55: 273-9.
31. Muramatsu Y, Kurosaki R, Watanabe H, Michimata M, Matsubara M, Imai Y, et al. Expression of S-100 protein is related to neuronal damage in MPTP-Treated mice. Glia 2003; 42: 307-13.
32. Neumann A, Schinzel R, Palm D, Riederer P, Munch G. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. FEBS Lett 1999; 453: 283-7. (Pubitemid 29326664)
33. Nishiyama H, Knopfel T, Endo S, Itohara S. Glial protein S100B modulates long-Term neuronal synaptic plasticity. Proc Natl Acad Sci USA 2002; 99: 4037-42.
34. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int 2001; 39: 409-13.
35. Petzold A, Brettschneider J, Jin K, Keir G, Murray NM, Hirsch NP, et al. CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barre syndrome. Muscle Nerve 2009; 40: 42-9.
36. Petzold A, Jenkins R, Watt HC, Green AJ, Thompson EJ, Keir G, et al. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neurosci Lett 2003; 336: 167-70.
37. Roche S, Cassidy F, Zhao C, Badger J, Claffey E, Mooney L, et al. Candidate gene analysis of 21q22: support for S100B as a susceptibility gene for bipolar affective disorder with psychosis. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1094-6. (Pubitemid 350207788)
38. Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003; 60: 614-32.
39. Schaf DV, Tort AB, Fricke D, Schestatsky P, Portela LV, Souza DO, et al. S100B and NSE serum levels in patients with Parkinson's disease. Parkinsonism Relat Disord 2005; 11: 39-43.
40. Sorci G, Bianchi R, Riuzzi F, Tubaro C, Arcuri C, Giambanco I, et al. S100B protein, a damage-Associated molecular pattern protein in the brain and heart, and beyond. Cardiovasc Psychiatry Neurol 2010; 2010, pii: 656481.
41. Sriram K, Benkovic SA, Hebert MA, Miller DB, O'Callaghan JP. Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-Tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo? J Biol Chem 2004; 279: 19936-47.
42. Steiner J, Bielau H, Bernstein HG, Bogerts B, Wunderlich MT. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 2006; 77: 1284-7. (Pubitemid 44654765)
43. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-Tetrahydropyridinetreated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997; 77: 1037-48.
44. Teismann P, Sathe K, Bierhaus A, Leng L, Martin HL, Bucala R, et al. Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol Aging 2012; 33: 2478-90.
45. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003; 100: 5473-8. (Pubitemid 36542729)
46. Van Eldik LJ, Zimmer DB. Secretion of S-100 from rat C6 glioma cells. Brain Res 1987; 436: 367-70.
47. Villarreal A, Aviles Reyes RX, Angelo MF, Reines AG, Ramos AJ. S100B alters neuronal survival and dendrite extension via RAGE-mediated NF-kappaB signaling. J Neurochem 2011; 117: 321-32.
48. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2,3,6-Tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002; 22: 1763-71.
49. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-97.